Objective: Low incidence of Pott's Puffy tumor (PPT) has caused studying risk factors and recurrences of the disease to be difficult. We used the comparatively increased incidence at our institution to evaluate potential risk factors for the disease process itself and prognostic factors for recurrence of the disease.

Methods: Single institutional retrospective chart review identified 31 patients from 2010 to 2022 with PPT compared with a control group of 20 patients with either chronic rhinosinusitis or recurrent sinusitis. Patient mean age of PPT was 42 (range of 5 to 90) with the majority of the patient population as male (74%) and Caucasian (68%) in the setting of rural West Texas. Patient mean age of the control group was 50.7 (range of 30-78) with majority of patient population as male (55%) and Caucasian (70%). Interventions studied were functional endoscopic sinus surgery (FESS), FESS with trephination, and cranialization with or without FESS to compare prognostic factors for recurrence rates of PPT. These patients' prognostic risk factors for recurrence and risk factors to develop PPT were analyzed using Analysis of Variance (ANOVA) χ 2 statistical analysis with Fischer exact testing.

Results: Mean age was 42 years (range of 5-90) with the majority of the PPT patient population as male (74%) and Caucasian (68%) with an overall incidence of about 1 in 300,000. Pott's Puffy tumor patients were significantly favored in the younger and male population compared with the control patients. Risk factors of no prior allergy diagnosis, previous trauma, medication allergy to penicillin class or cephalosporin class, and lower body mass index were significant in the PPT population compared with the control group. Significant prognostic factors for recurrence of PPT were prior history of sinus surgery and operative treatment choice. Fifty percent (3/6) of patients with prior sinus surgery had recurrence of PPT. Of our 4 treatment options (FESS, FESS with trephination, FESS with cranialization, or cranialization alone), ;FESS had a recurrence of PPT of 0% (0/13), FESS with trephination had a recurrence of PPT of 50% (3/6), FESS with cranialization had a recurrence of PPT of 11% (1/9), and cranizalization alone had a recurrence of PPT of 0% (0/3). Of note, postop chronic rhinosinusitis was seen in 46% (6/13) of FESS alone, 17% (1/6) with FESS with trephination, 0% (0/9) with FESS with cranialization, and 33% (1/3) with just cranialization alone.

Conclusions: Pott's Puffy tumor patients were younger and predominately male when compared to the control patients. No prior allergy diagnosis, previous trauma history, medication allergy to penicillin class or cephalosporin class, and lower body mass index are risk factors for PPT. There are 2 prognostic factors that predict recurrence of PPT: first operative treatment choice and prior sinus surgery. History of prior sinus surgery tends to increase the recurrence of PPT. The first operative treatment plan is the best shot at definitively treating PPT. Correct management surgically can prevent recurrence of PPT as well as long-term recurrence of chronic rhinosinusitis. With early diagnosis and mild disease, FESS is sufficient to prevent recurrence of PPT but chronic sinusitis may continue to occur if frontal sinus outflow track is not well opened. If considering trephination, a definitive cranialization may be more suited for more advanced disease since our study showed 50% of recurrence of PPT with trephination and FESS along with 17% chronic sinusitis long term. More advanced diseases with higher WBCs and intracranial extension do better with more aggressive surgical management with a cranialization with or without FESS which shows to reduce rates of PPT recurrence significantly.

Download full-text PDF

Source
http://dx.doi.org/10.1097/SCS.0000000000009451DOI Listing

Publication Analysis

Top Keywords

recurrence ppt
44
risk factors
24
ppt
21
sinus surgery
20
pott's puffy
16
prognostic factors
16
recurrence
16
factors recurrence
16
compared control
16
fess trephination
16

Similar Publications

Recurrent Pleomorphic Adenoma Presenting as a Giant Parapharyngeal Mass.

Ear Nose Throat J

January 2025

Department of Otolaryngology-Head and Neck Surgery, Al-Bairuni University Hospital, Faculty of Medicine, Damascus University, Damascus, Syria.

Article Synopsis
  • Pleomorphic adenoma (PA) is a common benign tumor of the salivary glands, often recurs and can extend into the parapharyngeal space (PPS), complicating treatment.
  • A 45-year-old male with a history of limited PA excision presented with a growing neck mass and related symptoms; MRI revealed a large tumor in the PPS.
  • Surgical removal involved a specialized neck approach, and the patient received postoperative radiotherapy, emphasizing the complexities and careful planning required for effective management of PPS tumors.
View Article and Find Full Text PDF

Introduction: Tracheomalacia (TM) often occurs in children with oesophageal atresia (OA), leading to recurrent respiratory symptoms and in severe cases to blue spells or ultimately respiratory arrest. In some patients, a secondary posterior tracheopexy may then be indicated. This secondary surgery, as well as respiratory morbidity, may be prevented by performing a primary posterior tracheopexy (PPT) concurrent with primary OA correction.

View Article and Find Full Text PDF

Advances in nanotechnology-based approaches for the treatment of head and neck squamous cell carcinoma.

RSC Adv

December 2024

State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University Chengdu Sichuan 610041 China.

Article Synopsis
  • - Head and neck squamous cell carcinoma (HNSCC) is a prevalent and aggressive cancer with high mortality rates, primarily due to traditional treatments like surgery, chemotherapy, and radiotherapy leading to poor survival outcomes and complications.
  • - Innovative therapies such as immunotherapy, photodynamic therapy, and photothermal therapy are limited by ineffective targeting and results, while early detection methods are hindered by various challenges.
  • - The rise of nanotechnology offers promising new strategies for HNSCC treatment through the use of nanoparticles (NPs), which can enhance drug delivery and targeting to tumors, showcasing unique advantages and highlighting the need for further research to overcome existing clinical hurdles.
View Article and Find Full Text PDF

Estrogen receptor α aggravates intestinal inflammation via promoting the activation of NLRP3 inflammasome.

Int Immunopharmacol

December 2024

MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, Jiangsu Province, China. Electronic address:

Activation of the NLRP3 inflammasome and estrogen receptor α (ERα) has been shown to increase the risk of inflammatory bowel diseases (IBD) or promote disease recurrence. In previous work, we demonstrated that ERα regulated the transcription of NLRP3. However, the precise mechanism by which ERα modulates NLRP3 in IBD models remains unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Pott's puffy tumor (PPT) is a rare infection of the frontal bone, posing serious neurological risks, and has been documented in cases involving immune dysfunction like Incontinentia pigmenti (IP).
  • A literature review found 12 cases of PPT linked to immune issues, with diabetes and iatrogenic immunosuppression as common causes; surgical intervention is the primary treatment.
  • PPT is increasingly recognized in patients with immune suppression, necessitating prompt and effective management to ensure better health outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!